TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04343807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS Block
Description: PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No nerve block will be performed and only intravenous nalbuphine will be given.
Study: NCT06486974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Na MFP
Description: Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
Study: NCT06557135

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Description: CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
Study: NCT05342792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Study: NCT06062355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9815 injection
Description: HRS-9815 injection
Study: NCT04974476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Training
Description: The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Training
Description: The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
Study: NCT06307795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS014004
Description: Varying doses of ANS014004
Study: NCT06192576

Intervention type: DRUG
Intervention: Olipudase alfa
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study: NCT05920577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergames and resistance training
Description: In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
Study: NCT06607705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with contact lens sensor
Description: Monitoring with contact lens sensor at 1-month pre-intervention visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with contact lens sensor
Description: Monitoring with contact lens sensor at 1-month pre-intervention visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with contact lens sensor
Description: Monitoring with contact lens sensor at 1-month post-intervention visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with contact lens sensor
Description: Monitoring with contact lens sensor at 3-months post-intervention visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with contact lens sensor
Description: Monitoring with contact lens sensor at 3-months post-intervention visit
Study: NCT06611358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping and Exercise
Description: Individuals meeting the inclusion criteria will receive kinesio taping applied to the temporomandibular joint by a physiotherapist every three days for two weeks. The kinesio tape will be applied along the origin-insertion line with zero tension. In addition to the kinesio taping, participants will follow a exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convansionel Exercise
Description: This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol.
Study: NCT06614972

Intervention type: DEVICE
Intervention: Balloon-expandable drug-eluting stent
Description: Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
Study: NCT06485596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XVIVO Heart Assist Transport System
Description: Direct procurement of donor hearts from DCD donation
Study: NCT06426433

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Exercises
Description: In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.

Intervention type: OTHER
Group type: OTHER
Intervention: Upper Extremity Exercises
Description: In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.

Intervention type: OTHER
Group type: OTHER
Intervention: Upper Extremity Exercises
Description: In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
Study: NCT05772208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 200mg qw
Study: NCT06613776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
Study: NCT05846165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field-Cycling Imaging (FCI)
Description: FCI scan
Study: NCT05799222

Intervention type: DIETARY_SUPPLEMENT
Intervention: Bariatrix Meal Replacement Products
Description: Meal replacement products offered through the Massachusetts General Hospital Weight Center.
Study: NCT06442995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
Description: When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of Isotonic saline + 2 mg morphine into the epidural space
Description: When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
Study: NCT05772208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy and CCRT
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy and CCRT
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy and CCRT
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
Study: NCT06308419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Sirolimus
Description: Given by IV
Study: NCT03883360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
Study: NCT05297201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - low dose
Description: CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - high dose
Description: CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
Study: NCT06660225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
Study: NCT06556355

Intervention type: OTHER
Intervention: neoadjuvant chemoradiation and McKeown esophagectomy
Description: Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen).
Study: NCT06660225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
Study: NCT06607484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-878
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT06625762

Intervention type: OTHER
Group type: OTHER
Intervention: Nantes bariatric surgery cohort
Description: The participants will be individuals living with obesity undergoing bariatric surgery
Study: NCT06626074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative MRI sequences
Description: additional sequences during MRI
Study: NCT06630741

Intervention type: OTHER
Intervention: alternative midwifery units (AMU)
Description: Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room
Study: NCT06630026

Intervention type: OTHER
Intervention: The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.
Description: • The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
Study: NCT06631261

Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention
Study: NCT06704633

Intervention type: DRUG
Group type: OTHER
Intervention: Sacubitril / Valsartan Oral Tablet
Description: A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
Study: NCT06706518

Intervention type: PROCEDURE
Intervention: Single-shot ablation technologies
Description: Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.~* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.~* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.~* 28 mm diameter PolarX balloon catheter\*.
Study: NCT06712420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0. PAtients will undergo curative surgery after neoadjuvant chemotherapy
Study: NCT05183984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-Awwb
Description: MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
Study: NCT06712420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative surgery
Description: Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative surgery
Description: Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification
Study: NCT06713135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vamorolone 40 mg/mL oral suspension
Description: Vamorolone is administered at a dose range between 2 mg/kg/day and 6 mg/kg/day for boys weighing \<40 kg. For boys weighing 40 kg or above, the dose range will be 80 mg to 240 mg once daily. Doses can be adjusted within the dose range as determined by the Investigator based on tolerability. The highest tolerated dose should be used.